Maroteaux - Lamy Syndrome: Report of Two Cases in Siblings

Rekha Puttannavar¹, Ravi Prakash B S², Mekhala Mukherjee³, Surupa Dutta⁴, Sharanya Bose⁵
¹Reader, ²Professor, ³,⁴Assistant Professor, ⁵P G Student
¹Department of Oral Medicine & Radiology, Guru Nanak Institute of Dental Sciences and Research. 157/F Nilgunj Road, Panihati, Kolkata – 700114
²,³,⁴Department of Periodontics. Guru Nanak Institute of Dental Sciences and Research. 157/F Nilgunj Road, Panihati, Kolkata – 700114

*Corresponding Author:
Prof (Dr) Ravi Prakash B S
157/F Nilgunj Road, Panihati, Kolkata – 700114
Email ID: drraviprakashbs@yahoo.com

Type of Publication: Case Report
Conflicts of Interest: Nil

Abstract
Mucopolysaccharidosis type VI (MPS VI), also known as Maroteaux-Lamy syndrome, is a progressive condition that causes many tissues and organs to enlarge, become inflamed or scarred, and eventually waste away (atrophy). Skeletal abnormalities are also common in this condition. The rate at which symptoms worsen varies among affected individuals. People with MPS VI generally do not display any features of the condition at birth. They often begin to show signs and symptoms of MPS VI during early childhood. The features of MPS VI affect many bodily systems, including skeletal, cardiac, and respiratory.

Keywords: Mucopolysaccharidosis, Maroteaux Lamy syndrome, Atrophy

INTRODUCTION

Mucopolysaccharidosis (MPS) is a rare autosomal recessive inherited glycosaminoglycan storage disease caused by the deficiency of arylsulfatase, also known as N acetyl glucosaminoglycans¹. It takes its name from the two French doctors Maroteaux and Lamy who first described the condition in 1963². It has been estimated that about 1 in 1,300,000 births are affected by MPS. Due to deficiency of Aryl sulfatase-B leads to accumulation of dermatan sulfate in tissues and their excretion in urine³.

At least 3 distinct ages of onset have been differentiated⁴:
• A severe infantile form, characterized by early onset and rapid disease progression
• An intermediate type is characterized by onset of disease in late childhood and
• A mild or adult form demonstrates onset after second decade.

Disease progression in the juvenile and adult form is typically slower than in infantile form.

Affected individual usually have retarded growth ranging from 90 to 140 cm, intelligence is not affected, large head, short neck, chubby cheeks, broad nose with flat bridge and wide nostrils. The shoulders are narrow and rounded and the stomach tends to protrude²,³. The hair on the body is coarser and more abundant than usual, and the eyebrows are bushy. Skin may become thickened and less elastic than usual.⁵ Neck is short contributing to breathing problems. Individuals with MPS may end up with secondary bacterial infections. Thick lips and enlarged tongue, broad alveolar ridges, widely spaced teeth with fragile enamel are some of intraoral features. Individuals with the syndrome may
develop heart failure and may have problem with aortic and mitral valve.\textsuperscript{6}

General manifestations include hepatosplenomegaly, umbilical or inguinal hernia, bowel problems like diarrhea significant problems with bone formation and growth called dysostosis multiplex, spine abnormalities like kyphosis, scoliosis, joint stiffness, short and broad hands with stubby fingers.\textsuperscript{4,5,6} Fingers stiffen and gradually become curved due to limited joint movement giving claw like appearance. Many people with MPS VI stand and walk with their knees and hips flexed.\textsuperscript{7} These combined with a tight Achilles tendon may cause them to walk on their toes and sometime have knock knees.\textsuperscript{7,8} Cloudy corneas due to storage of GAG, conductive deafness and carpal tunnel syndrome due to compression of nerve.\textsuperscript{9}

**Case Report:**

A 11-year-old son of normal intelligence of a consanguineous married parents came to the Outpatient Department with the chief complaint of his retained root stumps. Both were suffering from respiratory obstructive disorders and cardiac valvular disease (mitral valve) since early child hood. The girl patient had blurred vision since 4 years. General physical examination revealed noisy breathing and high respiratory rate of 24 cycles/min in female patient and 27 cycles/min in male.
Patients had distended abdomen with umbilical hernia, retarded growth (height being 142 cm of female patient and 140 cm of male patient) restricted joint movements of elbows and phalanges. Patient had spine abnormalities with droopy shoulders. Extraorally patients had large head, macrognathia, frontal bossing, and saddle nose with wide nostrils, coarse and bushy eyebrows, coarse facial hair, incompetent lips, cloudy corneas and short neck.

Intraorally patients had high arched palate with linear grooving at the center, macroglossia, fissured tongue, spacing between teeth, open bite, with over retention of deciduous dentition in the female patient.

Unerupted anterior teeth, incomplete root development of permanent anterior teeth, condylar aplasia, prominent gonial angle and increased follicular spaces having dentigerous cyst like appearances around unerupted molars.

Systemic examination revealed hepatosplenomegaly. Patients were referred by pediatrician for lab investigations for urine analysis which revealed abnormally high levels of GAG concentration in urine which was 594.70 mg gag / g creatinine (normal=19.97-110.53). Enzyme assay revealed abnormally
low levels of aryl sulfatase B that was 15.42 N mol/hr (normal >120 N mol/hr) which is pathognomonic sign of MPS.

- **Treatment plan:**
  1. Prompt treatment of respiratory infections from pulmonologist
  2. Prophylaxis against infective endocarditis before any dental or surgical procedure.
  3. Annual checkup with the cardiologist.

- **Dental Care:**
  1. Extraction of root stumps in relation to 84
  2. Preventive care: fluoride application
  3. Maintenance of oral hygiene
  4. Regular dental check up

**Conclusion:**
Although Maroteaux-Lamy syndrome is considered rare, these disorders are devastating for individuals and their families and result in considerable use of resources from healthcare systems; however the magnitude of the problem is not well defined. The introduction of Enzyme replacement therapy with Galsulfase has been a milestone in the treatment of MPS patients. This therapy opens the door to a more proactive approach of managing the disease, i.e., slowing down the accumulation of GAG rather than alleviating the resulting clinical manifestations.

**References:**
3. Dirk Isbrandt, Gabriele Arlt, Doug A. Brooks, John J. Hopwood, Kurt von Figura and Christoph Peters,